Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.46 |
| ▸ | MAOA | P21397 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411068 | 1.00 | MAOB (0.46) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3430302 | 0.90 | MAOB (0.48) | MAOBMAOAHRH3TOP1FFAR1 | |
| SCHEMBL3430304 | 0.90 | MAOB (0.48) | MAOBMAOAHRH3TOP1FFAR1 | |
| SCHEMBL13047892 | 0.80 | MAOB (0.49) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3410838 | 0.79 | MAOB (0.53) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3410834 | 0.79 | MAOB (0.53) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3408642 | 0.78 | MAOB (0.58) | MAOBMAOAHRH3TOP1 | |
| SCHEMBL13048353 | 0.77 | MAOB (0.49) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13048371 | 0.77 | MAOB (0.49) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3404627 | 0.74 | MAOB (0.53) | MAOBMAOANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2260017-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | MAOB 926/4885MAOA 1014/4885NPC1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.